Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Ellmén J[au]:

Entacapone and prostate cancer risk in patients with Parkinson's disease. Korhonen P et al. Mov Disord. (2015)

Pooled analysis of phase III with entacapone in Parkinson's disease. Kuoppamäki M et al. Acta Neurol Scand. (2014)

Entacapone did not Increase Prostate Cancer Risk or Mortality in Patients with Parkinson's Disease. Korhonen P et al. Value Health. (2014)

Search results

Items: 24

1.

Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial.

Trenkwalder C, Kuoppamäki M, Vahteristo M, Müller T, Ellmén J.

Neurology. 2019 Mar 26;92(13):e1487-e1496. doi: 10.1212/WNL.0000000000007173. Epub 2019 Mar 1.

2.

Oral Levosimendan Increases Cerebral Blood Flow Velocities in Patients with a History of Stroke or Transient Ischemic Attack: A Pilot Safety Study.

Kivikko M, Kuoppamäki M, Soinne L, Sundberg S, Pohjanjousi P, Ellmen J, Roine RO.

Curr Ther Res Clin Exp. 2015 Jan 29;77:46-51. doi: 10.1016/j.curtheres.2015.01.001. eCollection 2015 Dec.

3.

Entacapone and prostate cancer risk in patients with Parkinson's disease.

Korhonen P, Kuoppamäki M, Prami T, Hoti F, Christopher S, Ellmén J, Aho V, Vahteristo M, Pukkala E, Haukka J.

Mov Disord. 2015 Apr 15;30(5):724-8. doi: 10.1002/mds.26140. Epub 2015 Jan 16.

PMID:
25639262
4.

Entacapone did not Increase Prostate Cancer Risk or Mortality in Patients with Parkinson's Disease.

Korhonen P, Kuoppamäki M, Prami T, Hoti F, Christopher S, Ellmén J, Aho V, Vahteristo M, Pukkala E, Haukka J.

Value Health. 2014 Nov;17(7):A393. doi: 10.1016/j.jval.2014.08.870. Epub 2014 Oct 26. No abstract available.

5.

Pooled analysis of phase III with entacapone in Parkinson's disease.

Kuoppamäki M, Vahteristo M, Ellmén J, Kieburtz K.

Acta Neurol Scand. 2014 Oct;130(4):239-47. doi: 10.1111/ane.12278. Epub 2014 Sep 3.

PMID:
25186800
6.

The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations.

Ingman K, Naukkarinen T, Vahteristo M, Korpela I, Kuoppamäki M, Ellmén J.

Eur J Clin Pharmacol. 2012 Mar;68(3):281-9. doi: 10.1007/s00228-011-1121-5. Epub 2011 Sep 17.

PMID:
21927836
7.

Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa.

Kuoppamäki M, Sauramo A, Korpela K, Vahteristo M, Kailajärvi M, Lehtinen T, Ellmén J.

Int J Clin Pharmacol Ther. 2010 Nov;48(11):756-60.

PMID:
20979935
8.

Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.

Kuoppamäki M, Korpela K, Marttila R, Kaasinen V, Hartikainen P, Lyytinen J, Kaakkola S, Hänninen J, Löyttyniemi E, Kailajärvi M, Ruokoniemi P, Ellmén J.

Eur J Clin Pharmacol. 2009 May;65(5):443-55. doi: 10.1007/s00228-009-0622-y. Epub 2009 Feb 20.

PMID:
19229530
9.

Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome.

Polo O, Ylä-Sahra R, Hirvonen K, Karvinen J, Vahteristo M, Ellmén J.

Clin Neuropharmacol. 2007 Nov-Dec;30(6):335-44. Erratum in: Clin Neuropharmacol. 2008 Jan-Feb;31(1):61.

PMID:
18090458
10.

Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients.

Ellmén J, Hakulinen P, Partanen A, Hayes DF.

Breast Cancer Res Treat. 2003 Nov;82(2):103-11.

11.

Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.

Braybrooke JP, Vallis KA, Houlbrook S, Rockett H, Ellmén J, Anttila M, Ganesan TS, Harris AL, Talbot DC.

Cancer Chemother Pharmacol. 2000;46(1):27-34.

PMID:
10912574
12.

Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients.

Ellmén J, Werner D, Hakulinen P, Keiling R, Fargeot P, Falkson G, Bezwoda WR.

Cancer Chemother Pharmacol. 2000;45(5):402-8.

PMID:
10803924
13.

Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer.

Pyrhönen S, Ellmén J, Vuorinen J, Gershanovich M, Tominaga T, Kaufmann M, Hayes DF.

Breast Cancer Res Treat. 1999 Jul;56(2):133-43.

PMID:
10573106
14.

Re: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.

Mäenpää J, Ellmén J, Pasanen T, Kaukonen M.

J Natl Cancer Inst. 1999 Jun 2;91(11):972-3. No abstract available.

PMID:
10359551
15.

A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group.

Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmén J.

Breast Cancer Res Treat. 1997 Sep;45(3):251-62.

PMID:
9386869
16.

High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer.

Gershanovich M, Hayes DF, Ellmén J, Vuorinen J.

Oncology (Williston Park). 1997 May;11(5 Suppl 4):29-36.

PMID:
9165504
17.

High-dose toremifene in advanced renal-cell carcinoma.

Gershanovich MM, Moiseyenko VM, Vorobjev AV, Käpylä H, Ellmén J, Anttila M.

Cancer Chemother Pharmacol. 1997;39(6):547-51.

PMID:
9118468
18.

Toremifene concentration and multidrug resistance in lung tumors.

Liippo K, Ellmén J, Vänttinen E, Anttila M.

Cancer Chemother Pharmacol. 1997;39(3):212-6.

PMID:
8996522
19.

Ifosfamide combined with toremifene in the treatment of non-small cell lung cancer.

Salomaa ER, Liippo K, Ellmen J, Komi J.

Lung Cancer. 1996 Dec;16(1):75-80.

PMID:
9017586
21.

[Antibiotic treatment of bacterial meningitis in children--results from a Finnish multicenter study].

Anttila M, Anttolainen I, Ellmén J, Eskola J, Joki T, Kaartinen L, Kaski U, Kataja M, Kojo N, Korppi M, et al.

Duodecim. 1991;107(3):149-57. Finnish. No abstract available.

PMID:
1364751
22.

Fleroxacin versus standard therapy in gonococcal urethritis.

Lassus A, Renkonen OV, Ellmén J.

J Antimicrob Chemother. 1988 Oct;22 Suppl D:223-5.

PMID:
3144542
23.

Serum levels of vitamin A, E, and selenium in women with lichen sclerosus of the vulva treated with etretinate.

Romppanen U, Tuimala R, Ellmén J, Koskinen T, Pyykkö K.

Gynecol Obstet Invest. 1988;25(1):66-9.

PMID:
3343023
24.

[Oral treatment of vulvar dystrophy with an aromatic retinoid, etretinate].

Romppanen U, Tuimala R, Ellmén J, Lauslahti K.

Geburtshilfe Frauenheilkd. 1986 Apr;46(4):242-7. German.

PMID:
3710121

Supplemental Content

Loading ...
Support Center